Dow Jones 30 Stocks SEC Filings — March 09, 2026

09-03-2026

Aureus Greenway Holdings Inc. (AGH) entered into an Agreement and Plan of Merger dated March 8, 2026, with Autonomous Power Corporation, Aureus Merger Sub Inc., and Andrew Fox as Stockholder Representative, under which AGH's wholly-owned subsidiary will merge with Autonomous Power, surviving as a wholly-owned subsidiary of AGH. The Parent Board and Company Board unanimously approved the transaction, with requisite stockholder consents to be delivered promptly, and the merger is intended to qualify as a tax-free reorganization under Section 368(a) of the Code. AGH will amend its charter to change its name to Powerus Corporation effective at closing.

• ·Filing Date: March 09, 2026
• ·Agreement Date: March 8, 2026
• ·Closing to occur on second Business Day after satisfaction of conditions in Article VI
• ·Simultaneous execution of Lock-Up Agreements (Exhibit A) by Company Significant Holders and Leak-Out Agreements (Exhibit B) by Parent Significant Holders, effective at Closing
• ·Parent name change to Powerus Corporation via Parent Charter Amendment

09-03-2026

Amex GBT reported strong Q4 FY2025 revenue of $792M (+34% YoY) and full-year revenue of $2.718B (+12% YoY), driven by the CWT acquisition, with Adjusted EBITDA of $130M (+17%) and $532M (+11%) respectively; however, gross margins declined 243bps to 55% in Q4 and 15bps to 57% FY, Adjusted EBITDA margins fell 233bps to 16% in Q4 while flat at 20% FY, and free cash flow dropped sharply to $13M (-66%) in Q4 and $104M (-37%) FY. The company reiterated FY2026 guidance for 19-21% revenue growth to $3.235B-$3.295B and Adjusted EBITDA of $615M-$645M (+16-21%), doubled share buyback authorization to $600M, and highlighted 96% customer retention and $3.3B in Total New Wins Value.

• ·Q4 TTV growth of 45% and Transaction Growth of 37%, FY TTV 17% and Transaction Growth 14%, primarily due to CWT acquisition, business travel demand, and share gains.
• ·Excluding CWT, Q4 revenue growth was 8%.
• ·Net Debt / LTM Adjusted EBITDA improved slightly to 1.9x from 1.8x.
• ·CWT acquisition closed in September 2025.
• ·Next-gen Egencia launching in April 2026 with AI features.

09-03-2026

Transcat, Inc. (Nasdaq: TRNS) appointed Jaime Irick as President and Chief Executive Officer effective March 29, 2026, succeeding Lee D. Rudow, who is retiring after 14 years but will serve as a senior advisor through March 2027. Irick, a proven leader with experience at Pittsburgh Paints Company (including a $2B carve-out) and PPG Industries (overseeing $3B in revenue and 7,000+ employees), was also added to the Board and Executive Committee. Chairman Gary Haseley highlighted Irick's track record in growth, integrations like the $1.1B Ennis-Flint deal, and shareholder value creation.

• ·Jaime Irick holds a degree in Systems Engineering from the United States Military Academy at West Point and an MBA from Harvard Business School; prior U.S. Army Field Artillery Officer and Airborne Ranger.
• ·Irick plans to meet investors and analysts after Transcat’s Fourth Quarter and Full Year 2026 conference call and webcast.
• ·Transcat provides services to regulated industries including Life Science (pharmaceutical, biotechnology, medical device), aerospace/defense, energy/utilities; operates calibration labs in U.S., Puerto Rico, Canada, Ireland.

09-03-2026

Voyager Technologies reported record Q4 2025 net sales of $46.7M, up 24% YoY (46% adjusted), and full-year sales of $166.4M, up 15% YoY (27% adjusted), driven by 63% YoY growth in Defense and National Security to $35.7M in Q4, while Space Solutions declined 29% YoY to $12.5M due to NASA contract wind-down; full-year backlog hit a record $265.6M (+33% YoY) with liquidity at $704.7M (+15% sequential). However, the company posted Q4 net loss of $30.2M and full-year net loss of $116.1M, alongside raised 2026 revenue guidance of $225-255M (35-53% YoY growth). Five strategic acquisitions, including ExoTerra Resource and Estes Energetics, bolstered capabilities.

• ·Q4 non-GAAP adjusted loss of $21.7M and adjusted loss per share of $(0.37); full year non-GAAP adjusted loss of $82.4M and adjusted loss per share of $(2.05).
• ·Q4 Non-GAAP Adjusted EBITDA of $(21.8)M; full year $(69.9)M.
• ·Q4 innovation spend 132% of net sales on consolidated basis.
• ·Starlab achieved 10 NASA milestones in 2025 (4 in Q4), 31 total to date.
• ·Earnings conference call scheduled for March 10, 2026, at 9 a.m. ET.

09-03-2026

Universal Logistics Holdings, Inc. announced on March 3, 2026, that its condensed consolidated financial statements for the quarter ended September 27, 2025, should no longer be relied upon due to an error in the goodwill impairment analysis for its intermodal reporting unit, requiring a $43.2 million additional goodwill impairment charge that fully impairs the unit's goodwill. The error stemmed from including $46.7 million of inappropriate deferred tax liabilities in the carrying value. While the correction does not affect revenues, operating cash flows, liquidity, or debt covenant compliance, the company plans to file an amended 10-Q and has noted it in the context of a previously disclosed material weakness in internal controls.

• ·Error identified during Q4 2025 goodwill impairment review procedures.
• ·Company intends to file Amendment No. 1 to Form 10-Q for quarter ended September 27, 2025, as soon as practicable.
• ·Discussed with Audit Committee and independent auditors Grant Thornton LLP.
• ·Relates to previously disclosed material weakness in internal control over financial reporting.

09-03-2026

American Strategic Investment Co. (NYSE: NYC) filed an 8-K on March 9, 2026, under Items 7.01 and 9.01, disclosing a press release dated March 9, 2026, attached as Exhibit 99.1. The information in the filing and exhibit is furnished pursuant to Regulation FD and not deemed filed under the Exchange Act. The report was signed by Michael LeSanto, Chief Financial Officer.

• ·Securities registered: Class A common stock ($0.01 par value, NYSE: NYC); Class A Preferred Stock Purchase Rights (NYSE).
• ·Principal executive offices: 222 Bellevue Ave, Newport, Rhode Island 02840.
• ·Company details: Maryland incorporation, Commission File No. 001-39448, EIN 46-4380248.

09-03-2026

Innovation Beverage Group Limited filed a preliminary F-1 registration statement on March 9, 2026, for a proposed public offering of up to $15,000,000 through up to 4,166,667 Ordinary Units (each consisting of one Ordinary Share, one Series A Warrant, and one Series B Warrant) or Pre-Funded Units, with Aegis Capital Corp. as placement agent. The prospectus incorporates prior filings including Form 8-A from September 16, 2024, and details historical unregistered securities issuances from 2023-2024 totaling various small share grants and private placements exempt under Sections 4(a)(2), Reg D, Reg S, and Rule 701. No financial performance metrics or period-over-period comparisons are provided in this filing.

• ·Historical unregistered issuances include a 5:1 share consolidation in 2025 affecting share counts.
• ·F-1 amendments filed multiple times from February 28, 2025, through February 24, 2026.
• ·Company address: 29 Anvil Road, Seven Hills, NSW 2147, Australia.

09-03-2026

Artificial Intelligence Technology Solutions, Inc. (AITX) filed a Form 8-K on March 9, 2026, under Items 8.01 and 9.01, announcing the issuance of a press release titled 'The Top 20 Things You Probably Did Not Know About AITX and RAD', attached as Exhibit 99.1. The information is furnished and explicitly stated as not material or filed for liability purposes under the Exchange Act.

09-03-2026

This Rule 425 filing from Nuveen Municipal High Income Opportunity Fund (NMZ) urges shareholders of the Nuveen New Jersey Quality Municipal Income Fund to vote 'FOR' all proposals ahead of the March 19, 2026 shareholder meeting, as recommended by the Board. The communication emphasizes the importance of voting to meet quorum and avoid adjournment, offering phone voting assistance via Computershare. No financial metrics or performance data are provided.

• ·Shareholder meeting scheduled for Thursday, March 19, 2026.
• ·Phone voting available 9:00am-11:00pm ET weekdays and Noon-6:00pm ET Saturdays via toll-free number (reference provided).

09-03-2026

Hooker Furnishings Corporation (HOFT) filed a Form 8-K on March 9, 2026, reporting an event dated March 5, 2026, under Item 8.01 Other Events, announcing the issuance of a press release on March 6, 2026, attached as Exhibit 99.1. The filing was signed by C. Earl Armstrong III, Chief Financial Officer and Senior Vice-President - Finance. No financial or operational details from the press release are provided in the filing body.

• ·Date of earliest event reported: March 5, 2026
• ·Press release issuance date: March 6, 2026
• ·Securities: Common Stock, no par value (HOFT) on NASDAQ Global Select Market

09-03-2026

EVgo Inc.'s 10-K filing highlights operational strategies including efficient charging equipment procurement, technology-enabled products like Autocharge+ and the EVgo Public Network to enhance customer experience and efficiencies, and diversified charging revenue streams from retail, commercial fleets, and OEM partnerships. However, it emphasizes significant risks from evolving regulations such as the OBBBA terminating the 30C income tax credit, potential policy changes, inflation driving up costs, and U.S. tax law modifications that could adversely impact financial condition. These factors underscore a challenging regulatory and economic environment amid efforts to maintain market leadership in EV charging infrastructure.

• ·Filing Date: March 09, 2026
• ·Risks include termination of 30C income tax credit via OBBBA and potential tariff/sanctions changes

09-03-2026

Longeveron Inc. reported the immediate resignation of Board member and Audit Committee chairman Richard Kender on March 3, 2026, due to his new role as Executive Chairman and Interim CEO at Seres Therapeutics, resulting in temporary non-compliance with Nasdaq Listing Rule 5605(c)(2)(A) for lacking three independent audit committee members and a financial expert. On March 4, 2026, the company appointed existing Board member Dr. Roger Hajjar to the Audit Committee, restoring the minimum three independent members but still without a financial expert. Longeveron plans to appoint or elect a qualified independent audit committee financial expert within the 180-day cure period or at the next annual shareholders' meeting.

• ·Resignation not due to any disagreement with company operations, policies, practices, management, or Board.
• ·Seres Therapeutics announced Kender's new role on March 2, 2026.

09-03-2026

908 Devices Inc. reported total revenue of $56.2M for the year ended December 31, 2025, up 17.7% YoY from $47.7M in 2024, driven by strong growth in recurring revenue (+22.0% to $19.4M), U.S. state/local sales (+38.2% to $24.2M), rest of world (+21.4% to $14.4M), and global pharmaceutical/industrial (+98.7% to $3.0M). However, U.S. federal and defense revenue declined 13.6% to $14.5M, contract revenue fell 11.4% to $0.1M, and device sales growth slowed to 15.7% at $36.7M, amid risks from long sales cycles and heavy reliance on government contracts.

• ·Over 700 customers including major government institutions.
• ·Risks include long and unpredictable sales cycles, heavy dependence on U.S. government orders, and potential impacts from government contracting/fiscal policy changes.

09-03-2026

Battalion Oil Corporation entered into a definitive agreement to raise approximately $15 million gross ($14.1 million net after fees) through a private placement of common stock at $5.50 per share and/or prefunded warrants with a new institutional investor, with Roth Capital Partners as sole placement agent. The offering is expected to close on March 4, 2026, subject to customary conditions, with proceeds intended for working capital and general corporate purposes. The company also noted an increase in average oil production of approximately 1,200 net barrels per day in January compared to December.

• ·Expected closing date: March 4, 2026, subject to customary conditions
• ·Company to file resale registration statement on Form S-3 within 20 days of closing
• ·Securities offered in unregistered private placement under Securities Act exemptions
• ·Oil production increase of approximately 1,200 net barrels per day (January vs. December)

09-03-2026

Bunker Hill Mining Corp. closed a brokered LIFE offering of 150,808,332 units at C$0.18 for gross proceeds of C$27,145,500, a concurrent non-brokered private placement of 8,926,668 units for C$1,606,800, and a warrant exercise for C$5,000,000, totaling C$33,752,300 in aggregate proceeds. Net proceeds will fund working capital for the ramp-up of the Bunker Hill Mine to commercial production, exploration, and general corporate purposes. No declines or flat metrics reported; however, the offering involves dilution to existing shareholders and includes minor insider participation of 300,000 units.

• ·Each LIFE Unit includes one Common Share and one Warrant exercisable at C$0.30 for 36 months.
• ·Compensation Options exercisable at C$0.18 for 24 months.
• ·Insider participation relied on exemptions under MI 61-101.
• ·LIFE Units subject to 6-month U.S. hold period; registration statement to be filed within 5 business days.
• ·Announcement date: March 5, 2026; reverse split news releases: February 9, 2026 and March 3, 2026.

09-03-2026

Korn Ferry reported Q3 FY'26 fee revenue of $717.4 million, up 7% YoY (4% constant currency), driven by growth across all solutions including Executive Search (+13%), Consulting (+5%), Professional Search & Interim (+5%), Digital (+4%), and RPO (+3%). Net income attributable to Korn Ferry increased 12% YoY to $65.3 million (9.1% margin), adjusted EBITDA rose 8% to $123.1 million (17.2% margin), and estimated remaining fees reached $1.85 billion (+11% YoY). However, adjusted EBITDA margins were largely flat YoY across most solutions, Consulting hours worked declined 8% to 317 thousand, consultant headcounts decreased in Consulting (-7%) and Digital (-10%), and RPO new business fell sharply to $54.4 million from $209.9 million.

• ·Q4 FY'26 outlook: fee revenue $730M-$750M; diluted EPS $1.34-$1.40.
• ·YTD FY'26 fee revenue $2,147.7M (+6% YoY).
• ·Professional Search & Interim: Permanent Placement engagements billed 1,715 (flat YoY); Interim remaining fees $106.6M (-4% YoY).

09-03-2026

enGene Holdings Inc. reported a widened net loss of $29.8M for the three months ended January 31, 2026, up 21% YoY from $24.6M, driven by increased R&D expenses ($22.3M, +11%) and G&A expenses ($8.9M, +35%), with operating cash use rising to $28.9M from $25.7M. However, the company raised $126.3M gross from a public offering and $23.2M from pre-funded warrants, plus $25M from a Second Amended Term Loan, boosting total assets to $337.1M (up 52% QoQ from $221.5M) and shareholders' equity to $281.5M (up 68% QoQ). Cash and equivalents declined to $36.6M amid heavy investments in marketable securities.

• ·Loss per share improved to $0.44 from $0.48 YoY due to increased share count.
• ·Weighted-average shares outstanding: 67.3M in 2026 vs 51.0M in 2025.
• ·Marketable securities short-term increased to $239.3M from $143.6M QoQ.

09-03-2026

CMCT reported Q4 2025 net loss of $(17.7) million ($(11.20)/diluted share), wider than $(16.6) million ($(44.52)/diluted share) in Q4 2024, though FFO improved to $(7.1) million from $(8.7) million and Core FFO to $(5.9) million from $(7.0) million. Office portfolio was 74.8% leased (down from 81.7% YoY, but 88.5% excluding Oakland, up YoY), multifamily occupancy rose to 85.3% (NOI turned negative at $(0.87) million vs $0.86 million prior), hotel NOI flat at $2.1 million with improved RevPAR metrics, while total segment NOI grew 19% to $10.9 million. Completed First Western sale for $31.2 million net cash and announced March 2026 preferred stock redemption expected to improve annual FFO by $16.0 million.

• ·Office same-store portfolio 74.8% occupied and leased Dec 31 2025 (down 420bp and 380bp YoY same-store)
• ·Annualized rent per occupied sq ft same-store office $58.78 Dec 31 2025 vs $60.48 prior (down)
• ·Multifamily monthly rent per occupied unit $2,497 Dec 31 2025 (up YoY); net $2,127 (down YoY)
• ·Bay Area multifamily occupancy 88.4% Dec 31 2025 (up from 84.7% Q3 2025)
• ·1130 Howard office 100% occupied Dec 31 2025 (from 38.9% Q3 2025)
• ·Oakland Office mortgage matures Q3 2026
• ·Hotel RevPAR full year 2025 $152.70
• ·Redeemed 342,521 Series A1, 351,874 Series A, 4,122 Series D preferred shares in Q4 2025 into 1,910,435 common shares

09-03-2026

On March 3, 2026, Lightpath Fiber Issuer LLC, a bankruptcy-remote indirect subsidiary of Optimum Communications, Inc., completed a $1.657B securitization financing by issuing Secured Fiber Network Revenue Notes, Series 2026-1, consisting of $1.527B Class A-2 Notes at 5.597% interest and $130M Class B Notes at 5.890% interest. The net proceeds were used to repay in full $1,553.3M of existing debt, including 5.625% senior notes due 2028, 3.875% senior secured notes due 2027, and a term loan facility, with remaining proceeds for general corporate purposes. The notes are secured by fiber network assets and customer contracts in New York City, Boston metro areas, New Jersey, Connecticut, Pennsylvania, and Virginia, with an anticipated repayment date of March 25, 2031, and legal final maturity in March 2056.

• ·Notes subject to rapid amortization if debt service coverage ratio fails to meet thresholds.
• ·Securitized assets include fiber network assets and customer contracts in New York City, Boston metro areas, New Jersey, Connecticut, Pennsylvania, and Virginia.
• ·Legal final maturity date of the Notes: March 2056.

09-03-2026

Korro Bio, Inc. (KRRO) announced an oversubscribed $85M PIPE financing led by Venrock Healthcare Capital Partners with participation from new and existing investors, expected to close on or about March 10, 2026. Gross proceeds, combined with $85.2M in unaudited cash, cash equivalents, and marketable securities as of December 31, 2025, are expected to extend the cash runway into the second half of 2028 to fund clinical milestones for KRRO-121 in urea cycle disorders and the GalNAc-conjugated AATD program. The financing involves selling 4,501,928 common shares at $11.11 each and pre-funded warrants for 3,148,836 shares.

• ·PIPE closing subject to customary conditions on or about March 10, 2026
• ·Placement agents: Citigroup, Cantor, Oppenheimer & Co., William Blair
• ·Company to file SEC registration for resale of PIPE shares and warrant shares
• ·Cash runway extends into second half of 2028

09-03-2026

Heritage Insurance Holdings reported record Q4 2025 net income of $66.7 million, up 228.5% YoY from $20.2 million, driven by a net combined ratio of 62.0% (improved 27.7 points from 89.7%) and net loss ratio of 31.3% (down 23.4 points); full-year 2025 net income was $195.6 million, up 217.8% YoY from $61.5 million. However, gross premiums written declined 0.7% to $336.2 million, policies in force dropped 8.3% to 357,275, premiums in force were flat at $1.43 billion (down 0.1%), and gross premiums earned grew only 0.4% to $361.7 million. Book value per share increased 72.5% to $16.39 from year-end 2024.

• ·New business premium production increased 60.4% in Q4 2025 vs Q4 2024.
• ·Net weather losses $7.7M in Q4 2025 accident quarter (down from $45.6M prior year).
• ·Unpaid losses and LAE declined to $579.5M from $1.04B at Dec 31 2024.
• ·Reinsurance recoverable on claims declined to $318.6M from $740.2M at Dec 31 2024.
• ·Florida policies in force down 7.7% to 123,437; Other States down 8.5% to 233,838.
• ·Share repurchase authorization increased to $25M through Dec 31 2026.
• ·Dividend suspension continued to prioritize growth.

09-03-2026

Corbus Pharmaceuticals reported encouraging CRB-701 Phase 1/2 data at ESMO 2025 with unconfirmed ORR of 47.6% in HNSCC, 37.5% in cervical cancer, and favorable safety; CRB-913 Phase 1a showed 2.9% placebo-adjusted weight loss at 14 days with good GI tolerability. The company raised $75M in a Q4 public offering, extending cash runway to $163.3M into 2028. However, Q4 net loss widened to $20.6M ($1.25/share) from $9.5M ($0.78/share) YoY due to operating expenses rising 74% to $22.0M, primarily from R&D, and full-year net loss increased to $78.5M from $40.2M.

• ·CRB-601 Phase 1 completed and deprioritized; no additional patients planned.
• ·FDA Fast Track designations for CRB-701 in HNSCC and cervical cancer.
• ·Upcoming: CRB-701 FDA update Q1 2026, monotherapy data mid-2026, +Keytruda combo Q4 2026; CRB-913 CANYON-1 completion summer 2026.
• ·No grade 4/5 treatment-related AEs for CRB-701; low peripheral neuropathy and skin toxicity.
• ·CRB-913: highest SAD dose 600 mg/day, MAD 150 mg/day; no vomiting, constipation, nausea; negative neuropsychiatric assessments.

09-03-2026

ZIM Integrated Shipping Services Ltd. reported $6.9B in income from voyages for FY 2025, down 18% YoY from $8.4B in 2024, driven by a 2.3% decline in TEU volumes to 3.66M and a 17.8% drop in average freight rates to $1,551 per TEU; net income fell sharply to $482M from $2.15B, with gross profit margin contracting to 19.1% from 33.0% and Adjusted EBIT margin to 12.8% from 30.3%. While Intra-Asia and Latin America trades saw modest volume growth of 4.3% and 2.3% respectively, Pacific, Cross-Suez, and Atlantic-Europe experienced volume declines of 1.7%-13.6% and revenue drops up to 34.8%. Compared to FY 2023's $2.69B net loss, 2025 showed improvement but highlighted softening freight market dynamics.

• ·2M Alliance between Maersk and MSC terminated effective January 2025.
• ·Special State Share held by State of Israel requires maintaining at least 11 owned seaworthy vessels, majority Israeli board including chairperson, Israeli CEO, and consent for >35% share transfers.
• ·FY 2025 impairment reversal of $137M on assets (vs $2.06B loss in 2023).
• ·Filing date: March 09, 2026.

09-03-2026

Voyager Therapeutics reported Q4 2025 collaboration revenue of $15.3 million, up 144% YoY from $6.3 million, driven by Neurocrine agreement recognition, but full-year 2025 revenue declined 50% YoY to $40.4 million from $80.0 million due to lower prior-year milestones. Net loss narrowed to $27.4 million in Q4 from $34.5 million YoY, while full-year net loss widened significantly to $119.7 million from $65.0 million; R&D and G&A expenses remained relatively flat to slightly higher YoY. The company ended 2025 with $202 million in cash, supporting runway into 2028, with key pipeline milestones including VY1706 first-in-human dosing and VY7523 data expected in H2 2026.

• ·Neurocrine triggered $3 million milestone payment to Voyager in Q4 2025 for preclinical toxicology study initiation.
• ·Weighted-average common shares outstanding basic: 58.7 million (FY 2025) vs 57.7 million (FY 2024).

09-03-2026

ALX Oncology Holdings Inc. reported a narrowed net loss of $101.7M for the year ended December 31, 2025, improving 25% YoY from $134.9M in 2024, primarily due to a 27% reduction in total operating expenses to $104.0M, with R&D expenses declining 34% to $77.0M and G&A down 9% to $23.9M. However, total assets shrank 60% to $59.0M from $147.8M, driven by a drop in short-term investments to $28.4M from $110.2M and cash equivalents to $16.4M from $17.6M, while stockholders' equity fell to $26.0M from $113.6M and interest income decreased 58%. Cash used in operations improved to $84.1M from $121.9M, but net cash decreased amid limited financing inflows.

• ·Impairment charge of $3.2M recorded in 2025.
• ·Weighted-average shares used for net loss per share: 53,658,399 in 2025 vs 52,174,904 in 2024.
• ·Net loss per share improved to $(1.90) from $(2.58) YoY.
• ·ATM offering proceeds: $1.7M in 2025 vs $29.7M in 2024.

09-03-2026

Stock Yards Bancorp, Inc. (SYBT) filed an S-4 registration statement on March 9, 2026, related to its proposed merger with Field & Main Bancorp, under a fixed exchange ratio of 0.6550 SYBT shares per Field & Main share, implying a $44.55 value per Field & Main share based on SYBT's $68.01 closing price on January 26, 2026 (last trading day before merger announcement). Field & Main has 2,372,067 shares outstanding as of March 1, 2026, held by approximately 225 shareholders. The filing highlights ongoing dividends (SYBT at $0.32/share quarterly, Field & Main at $0.25/share) with coordination to avoid overlaps, but cautions on market price fluctuations, integration risks, and no assurance of merger completion.

• ·SYBT common stock trades on NASDAQ under symbol 'SYBT'; Field & Main common stock has no public market.
• ·Field & Main declares dividends in April, July, October, and December (paid January).
• ·Merger agreement prohibits Field & Main from paying dividends beyond customary quarterly amounts.

09-03-2026

Vicarious Surgical reported Q4 2025 total operating expenses of $9.3M, down 38% YoY from $15.0M, with GAAP net loss narrowing to $10.5M from $13.9M; full year 2025 operating expenses fell 25% YoY to $50.0M, and GAAP net loss improved to $50.2M from $63.2M, while cash burn of $45.1M was below initial $50M guidance. However, the company ended 2025 with only $9.8M in cash and investments, and anticipates $19M cash burn in 2026 amid ongoing pre-revenue status and net losses.

• ·FY 2026 expected cash burn of approximately $19M.
• ·Cash and cash equivalents $2.6M and short-term investments $7.2M as of Dec 31, 2025.
• ·Weighted average shares basic and diluted: 6.7M in Q4 2025 (up from 5.9M in Q4 2024).

09-03-2026

Optex Systems Holdings, Inc. held its 2026 annual shareholder meeting on March 9, 2026, with 5,814,286 shares present out of 6,937,358 outstanding, meeting quorum requirements. All five director nominees—Chad M. George, Dayton Judd, Dale E. Lehmann, R. Rimmy Malhotra, and Danny R. Schoening—were elected with for votes ranging from 3,813,077 to 3,995,478, despite some withhold votes up to 231,316 and 1,769,893 broker non-votes. Shareholders also ratified Whitley Penn LLP as the independent auditor for the fiscal year ending September 27, 2026, with overwhelming support of 5,802,742 for votes against 10,622 against and 922 abstentions.

• ·Director withhold votes: Chad M. George (50,812), Dayton Judd (122,632), Dale E. Lehmann (48,915), R. Rimmy Malhotra (231,316), Danny R. Schoening (105,309)
• ·Auditor ratification: Against (10,622), Abstain (922)

09-03-2026

Independent Bank Corp. (INDB) filed an 8-K on March 9, 2026, under Regulation FD Disclosure, attaching an investor presentation (Exhibit 99.1) to be used at the 2026 RBC Capital Markets Global Financial Institutions Conference on March 10, 2026. The filing includes no financial results or performance metrics. Signed by Chief Financial Officer Mark J. Ruggiero.

• ·Filing Items: 7.01 (Regulation FD Disclosure), 9.01 (Financial Statements and Exhibits)
• ·Commission File Number: 0000776901
• ·I.R.S. Employer Identification No.: 04-2870273

09-03-2026

Liberty Broadband Corporation announced on March 6, 2026, that it will hold its virtual Annual Meeting of Stockholders on May 11, 2026, at 11:15 a.m. Mountain Time. The disclosure was furnished under Regulation FD via Form 8-K with an attached press release (Exhibit 99.1). No financial or operational metrics were reported.

• ·Securities registered: Series A common stock (LBRDA), Series C common stock (LBRDK), Series A Cumulative Redeemable preferred stock (LBRDP), all on Nasdaq Stock Market LLC.
• ·Principal executive offices: 12300 Liberty Blvd., Englewood, Colorado 80112.
• ·Date of earliest event reported: March 6, 2026; Filing date: March 9, 2026.

09-03-2026

Repay Holdings Corp reported FY2025 revenue of $309.3M, a 1.2% YoY decline from $313.0M in FY2024, driven by an 8.5% drop in Business Payments to $48.4M despite a 1.7% increase in Consumer Payments to $285.9M. The company posted a net loss of $271.1M, significantly wider than $10.3M in 2024, primarily due to a $242.7M non-cash impairment loss, while Adjusted EBITDA fell 8.7% to $128.6M. Total assets decreased to $1.2B from $1.6B, reflecting goodwill impairment, and operating cash flow dropped to $91.1M from $150.1M.

• ·Goodwill decreased to $474.5M from $716.8M as of Dec 31, 2025 vs 2024.
• ·Cash and cash equivalents fell to $115.7M from $189.5M.
• ·Long-term debt, net reduced to $280.1M from $496.8M.

09-03-2026

Liberty Live Holdings, Inc. announced on March 6, 2026, that it will hold its virtual Annual Meeting of Stockholders on May 11, 2026, at 12:00 p.m. Mountain Time. The disclosure was made pursuant to Regulation FD via Form 8-K Item 7.01, with the press release attached as Exhibit 99.1.

09-03-2026

U.S. Physical Therapy, Inc. (USPH) updated its investor presentation on March 6, 2026, for the year ended December 31, 2025, highlighting 780 owned/managed outpatient physical and occupational therapy clinics across 44 states, $781M TTM revenues with 16% YoY growth, and $95M TTM Adjusted EBITDA. The company generates 85% of revenue from physical therapy operations and 15% from injury prevention services, operating in a highly fragmented >$40B U.S. rehabilitation market where no company holds more than 10% share, and maintains a $1.80 annual dividend.

• ·Headquartered in Houston, TX; founded in 1990.
• ·10-K for year ended December 31, 2025 filed with SEC on February 27, 2026.
• ·Investor presentation available on www.usph.com under Investor Relations.

09-03-2026

Western Asset Investment Grade Opportunity Trust Inc. (NYSE: IGI) issued a definitive proxy statement for its Annual Meeting of Stockholders on April 17, 2026, to elect three Class II Directors and ratify PricewaterhouseCoopers LLP as independent auditors for the fiscal year ending November 30, 2026. The record date is February 6, 2026, with 5,993,650 shares of common stock outstanding. No financial performance metrics or period-over-period comparisons are disclosed in the filing.

• ·Annual Meeting location: One Madison Avenue, 17th Floor, New York, New York 10010 at 10:00 a.m. New York time
• ·Common Stock par value: $0.001 per share
• ·Fund fiscal year end: November 30
• ·Potential virtual/hybrid format changes to be announced via press release and EDGAR

09-03-2026

Western Asset Global Corporate Opportunity Fund Inc. (NYSE: GDO) issued a proxy statement for its annual stockholder meeting on April 17, 2026, at 10:00 a.m. ET in New York, NY, to elect three Class I Directors (Proposal 1) and ratify PricewaterhouseCoopers LLP as independent auditors for the fiscal year ending October 31, 2026 (Proposal 2). The record date is February 6, 2026, with 7,519,400 shares of common stock outstanding. No financial performance metrics or period-over-period comparisons are provided in the filing.

• ·Meeting location: One Madison Avenue, 17th Floor, New York, New York 10010
• ·Quorum requires majority of outstanding shares present in person or by proxy
• ·Proxies default to 'FOR' both proposals unless otherwise instructed

09-03-2026

MACOM Technology Solutions Holdings, Inc. held its 2026 Annual Meeting of Stockholders on March 5, 2026, where all eight director nominees were elected with strong majority support ranging from 63.3M to 69.3M votes for. Shareholders also approved, on an advisory basis, the compensation of named executive officers for fiscal year 2025 (69.3M for vs. 570K against) and ratified Deloitte & Touche LLP as the independent auditor for the fiscal year ending October 2, 2026 (71.7M for vs. 178K against). While all proposals passed overwhelmingly, some director nominees faced notable withheld votes, up to 6.6M for Jihye Whang Rosenband.

• ·Proposal 1 votes: Charles Bland (68,533,588 For, 1,386,445 Withheld); Stephen Daly (68,021,587 For, 1,898,446 Withheld); Peter Chung (65,875,278 For, 4,044,755 Withheld); Bryan Ingram (69,304,619 For, 615,414 Withheld); Geoffrey Ribar (68,499,669 For, 1,420,364 Withheld); John Ritchie (66,756,121 For, 3,163,912 Withheld); Jihye Whang Rosenband (63,335,903 For, 6,584,130 Withheld); Murugesan “Raj” Shanmugaraj (67,813,138 For, 2,106,895 Withheld).
• ·Proposal 2: 69,293,469 For; 569,953 Against; 56,611 Abstaining.
• ·Proposal 3: 71,708,151 For; 178,297 Against; 28,707 Abstaining.
• ·Meeting held in Chelmsford, Massachusetts.

09-03-2026

Zevra Therapeutics reported net revenue of $106.5M for 2025, up 350% YoY from $23.6M, driven by product sales including MIPLYFFA and OLPRUVA, leading to net income of $83.2M versus a $105.5M loss in 2024, primarily due to a $148.3M gain on PRV sale. However, the company recognized a $58.7M impairment of intangible assets, resulting in an ongoing operating loss of $62.9M (improved 28% from $87.0M prior year), with SG&A expenses rising 41% to $77.6M and intangible assets dropping to $6.4M from $69.0M. Cash and equivalents increased to $62.4M, with operating cash flow turning positive at near-breakeven versus $69.7M used previously.

• ·MIPLYFFA FDA approved Sep. 20, 2024; Orphan Drug Exclusivity through 2031; MAA submitted to EMA July 28, 2025.
• ·OLPRUVA FDA approved Dec. 22, 2022; IP through 2036.
• ·AZSTARYS FDA approved and partnered; receiving royalties and milestones; IP through 2037.
• ·Clinical programs: Celiprolol Phase 3 ongoing for VEDS (IP potential through 2038); KP1077IH Phase 3 ready for IH; KP1077N Phase 3 potential for Narcolepsy (both IP potential through 2038).
• ·Basic EPS $1.40 in 2025 vs $(2.28) in 2024.
• ·Total assets $284.7M as of Dec 31, 2025 (up from $178.1M); long-term debt $61.9M.

09-03-2026

Envirotech Vehicles, Inc. entered into a Securities Purchase Agreement dated March 6, 2026, to issue and sell debentures with an aggregate principal amount of up to $11M ($4M at First Closing and $7M at Second Closing) at a purchase price equal to 96% of the principal amount, along with warrants exercisable into 1,291,778 common shares as a commitment fee. The Second Closing is contingent on the effectiveness of the SEPA Registration Statement and must occur by June 30, 2026. Issuances are subject to a Nasdaq Exchange Cap of 2,584,850 common shares (19.99% of outstanding shares) without shareholder approval.

• ·First Closing to occur on first Business Day conditions are met, at 10:00 a.m. New York time
• ·Second Closing on first Business Day after SEPA Registration Statement declared effective by SEC
• ·Buyer is accredited investor acquiring Securities for investment purposes, not public distribution
• ·Securities include restrictive legends unless registered or Rule 144 applicable

09-03-2026

James E. Schisler, Chief Operating Officer of The Brand House Collective, Inc. (TBHC), announced his intent to resign effective March 20, 2026, to pursue other opportunities, with no disagreements with the Company. He will remain in his role until the departure date. The resignation was announced on March 4, 2026, with the 8-K filed on March 9, 2026.

• ·Principal executive offices: 5310 Maryland Way, Brentwood, Tennessee 37027
• ·Telephone: 615-872-4800
• ·Common Stock trading symbol: TBHC on NASDAQ Global Select Market